Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12311918 | 0.87 | HRH3 (0.51) | HRH3SMN1; SMN2MAOAMAOBHTR2C | |
| SCHEMBL15849021 | 0.87 | HRH3 (0.51) | HRH3SMN1; SMN2MAOAMAOBHTR2C | |
| SCHEMBL16513840 | 0.86 | HRH3 (0.50) | HRH3SMN1; SMN2MAOAMAOBHTR2C | |
| SCHEMBL5470273 | 0.85 | HRH1 (0.50) | HRH3SMN1; SMN2MAOAMAOBHRH1 | |
| SCHEMBL24716435 | 0.84 | PTGS1 (0.46) | HRH3HRH1CCR3ACACBPTGS1 | |
| SCHEMBL19155248 | 0.83 | CTSK (0.48) | HRH3SMN1; SMN2MAOAMAOBFPR2 | |
| SCHEMBL22278017 | 0.83 | HRH3 (0.48) | HRH3SMN1; SMN2MAOAMAOBFPR2 | |
| SCHEMBL20205884 | 0.83 | GRIN1 (0.43) | HTR2CHTR2BACACBPTGS1PTGS2 | |
| SCHEMBL13855674 | 0.83 | HRH3 (0.46) | HRH3HRH1CCR3FPR2PROKR1 | |
| SCHEMBL10057697 | 0.83 | HRH3 (0.62) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765949-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8148404-B2 | Modulators of CB1 receptors | 7TM PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-20100144701-A1 | Modulators of CB1 Receptors | 7TM PHARMA A/S (DK) | 2010-06-10 | — | — | US | disclosed |
| WO-2007009236-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144701-A1 | Modulators of CB1 Receptors | CNR1, CNR2, GPR6 | HRH3 127/4885SMN1; SMN2 3674/4885MAOA 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.